Switching from covalent BTKI to BCL2i is associated with improved clinical outcomes compared to switching to a different covalent BTKI in patients with CLL/SLL treated in the real-world settingToby A. Eyre,Catherine C. Coombs,Nicole Lamanna,Jennifer Brown,Beenish S. Manzoor,Nilanjan Ghosh,Hande H. Tuncer,Alan Skarbnik,Matthew Davids,Nnadozie Emechebe,Hasan Alhasani,Lori A. Leslie,Lindsey Roeker,Chaitra Ujjani,Isabelle Fleury,Barbara Eichhorst,Brian Hill,Joanna Rhodes,Frederick Lansigan,Paul Barr, Laurie Pearson, Christopher P. Fox,Yun Choi, Christopher E. Jensen, Dureshahwar Jawaid,Kaitlin Kennard,Irina Pivneva, Talissa Watson,Annie Guerin,Mazyar ShadmanLEUKEMIA & LYMPHOMA(2023)引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要